Evidence map›Paper›PMID 37615683›Full record

ArticlePsychopharmacology2023

Effort-related effects of chronic administration of the DA D

Renee A Rotolo, Alev Ecevitoglu, Rose E Presby, Hanna Lindgren, Cedric Mombereau, Cyrene Nicholas, Alana Moore, Gayle A Edelstein, Merce Correa, John D Salamone

Abstract read
PubMed Publisher
In one paragraph

Article in Psychopharmacology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.5field-weighted citation impact, top 33% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 3 citations in OpenAlex.

  1. Article
  2. Adenosine AFrontiers in pharmacology · 2024
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 5 institutions in 3 countries.

Renee A RotoloBehavioral Neuroscience, Department of Psychological Sciences, University of Connecticut, Storrs, CT, 06269-1020, USA.
Alev Ecevitoglu *Behavioral Neuroscience, Department of Psychological Sciences, University of Connecticut, Storrs, CT, 06269-1020, USA.
Rose E PresbyBehavioral Neuroscience, Department of Psychological Sciences, University of Connecticut, Storrs, CT, 06269-1020, USA.
Hanna LindgrenSymptom Biology, H. Lundbeck A/S, Ottiliavej 9, 2500, Valby, Denmark.
Cedric MombereauArea de Psicobiologia, Universitat Jaume I, Castelló, Spain.
Cyrene NicholasBehavioral Neuroscience, Department of Psychological Sciences, University of Connecticut, Storrs, CT, 06269-1020, USA.
Alana MooreBehavioral Neuroscience, Department of Psychological Sciences, University of Connecticut, Storrs, CT, 06269-1020, USA.
Gayle A EdelsteinBehavioral Neuroscience, Department of Psychological Sciences, University of Connecticut, Storrs, CT, 06269-1020, USA.
Merce CorreaArea de Psicobiologia, Universitat Jaume I, Castelló, Spain.
John D SalamoneBehavioral Neuroscience, Department of Psychological Sciences, University of Connecticut, Storrs, CT, 06269-1020, USA. john.salamone@uconn.edu.
University of Connecticut · USUniversitat Jaume I · ESLundbeck (Denmark) · DKSage Therapeutics (United States) · USScintillon Institute · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

rationaleLong-acting antipsychotics such as haloperidol decanoate are becoming more commonly used. Long-acting depot formulations have several advantages, but secondary negative effects of prolonged delivery, including motivational dysfunctions, could have debilitating effects. Assessing the behavioral changes that emerge during chronic antipsychotic administration in rats could provide insight regarding the development of motivational dysfunctions and drug tolerance.

objectivesAcute administration of dopamine D2 antagonists such as haloperidol induce motivational deficits in rats, as marked by a shift towards a low-effort bias during effort-based choice tasks. In the present studies, programmable subcutaneous infusion pumps provided continuous and controlled drug delivery of haloperidol. Animals were assessed using a fixed ratio (FR) 5 lever pressing schedule and the FR5/chow feeding test of effort-based choice. The adenosine A

resultsContinuous chronic infusions of haloperidol produced significant reductions in FR5 performance and a shift from lever pressing to chow intake in rats tested on FR5/chow feeding choice, with no evidence of tolerance over the 4-week infusion period. Behavior returned to baseline during the vehicle-infusion washout period. Istradefylline significantly reversed the effects of haloperidol, increasing lever pressing and decreasing chow intake in haloperidol-treated rats.

conclusionsThese studies provide an important behavioral characterization of the effects of chronically infused haloperidol, and demonstrate that A

Indexed as

Antipsychotic AgentsHaloperidolAdenosineAnimalsPurinesRatsAdenosineAntipsychotic AgentsHaloperidolistradefyllinePurinesAvolitionDopamineMotivationNegativeSchizophreniaSymptoms

Identifiers

PMID37615683
OpenAlexW4386116761

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.